Skip to content

XWEL

XWELL, Inc.

NASDAQ · Consumer Cyclical · Personal Products & Services · US

$0.98
+0.57%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 18, 2026
EPS estimate
-$1.00
Revenue estimate
$2.6M

Latest reported

Last report date
Aug 14, 2026
EPS actual
-$0.26
EPS estimate
-$1.00
Revenue actual
$7.1M
Revenue estimate
$2.6M

Track record

Trailing twelve quarters

EPS beats (12Q)
3
EPS misses (12Q)
3
EPS in line (12Q)
1
Avg surprise (4Q)
-15.9%
Revenue beats (12Q)
3
Earnings call summaryRead the full call →

Q3 FY2024 · Nov 14, 2024

AI summary of management’s prepared remarks and analyst Q&A · For informational purposes only, not investment advice

Management highlights

  • Ezra Ernst's background including his time with XWELL and prior senior management roles.
  • Transition to sole CEO, consolidating dual CEO structure, realigning resources, leaner decision-making, and cost reduction strategy.
  • Prioritizing out-of-airport brand strategy, planning to expand in Florida, open first Naples Wax location in November 2024, and operate up to 10 XWELL properties by mid-2025.
  • In-airport growth: solid foot traffic at XpresSpa at Philadelphia International Airport, plan to open Penn Station XpresSpa next year, tech-forward concept.
  • Partnership with Priority Pass enhancing brand awareness, expanding service menu, adding skilled retail and store management, simplifying spa appointment reservation via social media and mobile platforms.

Guidance

  • Plan to expand into several attractive markets in Florida and be in position to operate up to 10 XWELL properties by mid-2025.
  • Expect to share more regarding growth initiatives in 2025.
  • Focus on continued improvements in execution, prudent cost management, and enhanced operational processes.

Segment performance

For the third quarter, total revenue was approximately $8.4 million. Revenue primarily consisted of approximately $4.9 million from XpresSpa locations and Treat locations, which is about 58.3% of total revenue. Approximately $3.1 million came from XpresTest, including the biosurveillance partnership and HyperPointe business, making up around 36.9% of total revenue. Approximately $0.4 million was from Naples Wax Center, accounting for about 4.8% of total revenue. Salaries and benefits in the third quarter of 2024 were approximately $1.9 million, general and administrative expenses were approximately $4.5 million, total operating expenses were approximately $6.8 million. Operating loss was $4.8 million, net loss attributable to common shareholders was $4.8 million.

Analyst Q&A

Q: A: Q: A:

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 18, 2026